Misplaced Pages

This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 13:22, 16 December 2011 (Disambig Humanize, replaced: humanized monoclonal antibody → humanized monoclonal antibody using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis and of methicillin-resistant S. aureus.

It was developed by Inhibitex.

See also

• MSCRAMM (microbial surface components recognizing adhesive matrix molecules)

References

1. Clinical trial number NCT00198289 at ClinicalTrials.gov
2. PMID 18221183
3. John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Antiinfective agent stubs
• Monoclonal antibody stubs